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Collagen hydrolysates (CHs) are heterogeneous mixtures of collagen peptides that are often used 
as nutraceuticals for osteoarthritis (OA). In this study, we compared the peptide composition and 
pharmacological effects of three different CH preparations (CH-Alpha®, Peptan® B 2000 and 
Mobiforte®) as well as their production batches. Our biochemical analysis using MALDI-TOF mass 
spectrometry and the ICPL™-isotope labelling method revealed marked differences between 
different CH preparations and even between some production batches of the same preparation. We 
also investigated the pharmacological effects of these CHs on human fibroblast-like synoviocytes 
(FLS). No significant effects on cultured FLS could be demonstrated for either production batch of CH-
Alpha®, Peptan® B 2000, and Mobiforte® analyzing a small number of pharmacological relevant 
targets. Thus, our study already shows for the first time that different production batches of the same 
CH preparation as well as different CH preparations can differ significantly in their peptide composition. 
In this line, further studies are also needed to verify equal pharmacological efficacy of CH batches on 
a much broader range of (patho)physiological relevant targets. If OA patients are to be offered a safe 
and effective nutraceutical a better knowledge about all potential effects as well as ensuring the same 
active-substance levels are a prerequisite.
Osteoarthritis (OA) is the most common joint disorder affecting approximately 15% of the total1 and 60% of the 
elderly population2, in whom it causes pain, restriction of movement and disability2,3. During the progress of the dis-
ease, OA affects not only the articular cartilage, but also the entire joint including the subchondral bone, synovium, 
ligaments, and periarticular muscles, and as a low-grade systemic inflammation possibly the entire organism2–6. 
Since it has been shown that OA also has an inflammatory component mainly mediated via the release of soluble 
inflammatory factors, OA is no longer considered as a degenerative disease caused exclusively by aging and mechan-
ical stress6. The fact, that there is no cure for OA, and that treatments are not available for slowing progression down, 
has led in recent years to an increasing interest both in patients and the scientific community for alternative nutri-
tional treatments that produce reduced side-effects7–9. In the US, 47% of patients with OA were reported as using 
alternative treatments including food supplements and nutraceuticals9 such as collagen hydrolysates (CHs).
CHs consist of a mixture of different peptides obtained from collagen-containing tissues by hydrolytic and/or enzy-
matic degradation10–13, and they are generally considered as a safe food ingredient7. Since Oesser et al.14 published an 
in vitro study showing that CHs can stimulate the biosynthesis of collagen by chondrocytes of articular cartilage, CHs 
have gained a huge amount of public attention. Currently, many different CH preparations are commercially available 
from various companies who produce those using unpublished manufacturing processes. Collagenous proteins used 
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for the production of CHs are derived from bone and skin, or the scales and fins of various vertebrates10,12,15. As such 
the precise peptide profiles may differ between CH preparations and is often even unknown11,12,16.
However, the clinical efficacy of CHs with OA remains unclear: While some studies attested a pain-reducing 
effect17,18, this observation could not or only partly be confirmed in other studies13,19. Remarkably, Benito-Ruiz et al.17 
reported a significantly higher pain reduction in patients with less average meat and thus collagen consumption 
after taking a CH preparation. However, this effect was not found in patients who had high meat consump-
tion indicating that CH could be especially beneficial in patients with low meat intake. In addition, McAlindon 
et al.19,20 found some evidence for an anabolic effect on articular cartilage after orally administered collagen 
peptides in patients using MRI and biomarkers. However, these data are preliminary due to the small sample 
size, the missing morphometric MRI sequences, and no consistent correlation between PIIANP or CS846 with 
changes of the dGEMERIC score. It was concluded, that the evidence to recommend the generalized daily use of 
CHs for patients with OA is not sufficient and no health claim has been approved by the European Food Safety 
Authority21,22. Up until now, alleged effects of CHs have been attributed to the effect of CHs on cartilage tissue. 
Several studies by different working groups have been performed on cultured animal or human chondrocytes as 
well as cartilage explants to analyse the effects of CHs and endogenous collagen fragments. However, different and 
even contradictory results have been obtained in these studies11,12,14,23–25.
We already reported that human articular cartilage explants respond differently to various bovine, porcine 
or fish CH preparations11,12. Furthermore, we also found evidence that individual CH preparations induce an 
elevated release of proinflammatory mediators such as IL-6, PGE2, NO and various MMPs11,12. Some CHs even 
inhibited collagen biosynthesis in chondrocytes at high concentrations in vitro11,12. Using matrix-assisted laser 
desorption/ionisation (MALDI)-time of flight (TOF)-mass spectrometry (MS), nuclear magnetic resonance spec-
troscopy and atomic force microscopy, we were able to demonstrate that different CH preparations markedly dif-
fer in their biochemical composition11,12. As such, the term CH describes a heterogeneous group of non-fibrillar 
collagenous peptide mixtures and we assume that different effects of CHs are possibly related to variations in the 
compositions of bioactive peptides11,12. However, there is currently no information in the literature as to whether 
different batches of CH preparations differ with respect to their peptide profiles.
In 2010, Ohara et al.26 reported that proline-hydroxyproline (Pro-Hyp) peptides, frequently found in sera 
after oral ingestion of CHs26–28, stimulate hyaluronic acid synthesis by rabbit-derived fibroblast-like synoviocytes 
(FLS)26. However, the effects of exogenous and endogenous collagen fragments on synovial membranes or FLS are 
not currently known. Our study was therefore designed to fill this knowledge gap by systematically investigating 
the effects of exogenously administered CHs on FLS. Based on the results of our previous investigations11,12, the 
specific aim of our current study was (a) to further quantify the biochemical differences between the peptide 
profiles of different CH preparations using MALDI-TOF-mass spectrometry, and (b) to test for the first time the 
reproducibility of the composition of different batches of the same CH preparation. This was further substantiated 
biologically by determining whether different CH preparations as well as their batches possess bioactive peptides 
that induce the same cellular effects on FLS obtained from OA-patients.
Materials and Methods
Reagents. The bovine CH preparations Peptan® B 2000 (lot no. 1048665 and 1266793/x) and CH-Alpha® (lot 
no. L115/1031, L88/1031, L170/1031) were from Rousselot (Puteaux, France) and Quiris Healthcare (Gütersloh, 
Germany), respectively, whereas the porcine CH Mobiforte® (lot no. 11/2016/L07 and 11/2016/L06) was obtained 
from Astrid Twardy (Unterföhring, Germany). The batches of CH-Alpha® and Mobiforte® contained some 
additional ingredients such as fructose and vitamin C. Unless otherwise indicated, all reagents were purchased 
from Sigma (Deisenhofen, Germany). Dulbecco’s modified Eagle media (DMEM) and penicillin/streptomycin 
were from PAN Biotech (Aidenbach, Germany), SERVA ICPL™ kit was from SERVA (Heidelberg Germany), 
HEPES was from Invitrogen™ (Karlsruhe Germany), nitrate reductase was from Roche Diagnostics (Mannheim, 
Germany), and peqGold Trifast™ was from Peqlab Biotechnologie GmbH (Erlangen, Germany).
MALDI-TOF MS Analysis. As described earlier12, the numbers of peaks representing individual pep-
tides and the numbers of common peptides between CH preparations and their batches were estimated by 
Matrix-assisted laser desorption/ionization (MALDI)-time of flight (TOF)-mass spectrometry (MS) in reflec-
tor mode. In addition, the concentrations of peptides in different batches of CH preparations were compared 
using the Isotope Coded Protein Label (ICPL™) methodology. In order to remove impurities such as additional 
ingredients, 10 mg/ml of each CH batch were first dissolved in 0.1% trifluoroacetic acid (TFA) and subjected to 
reverse-phase solid-phase extraction (DSC-18, Supelco, Bellefonte, USA). Bound peptides were washed, eluted 
with 10 ml 0.1% TFA in 80% acetonitrile, and lyophilised after removal of excess acetonitrile using a speed vac. 
The samples were then re-solubilised in 1% TFA at a concentration of 10 mg/ml.
For the quantitative comparison of two batches from one CH preparation, each purified batch was labelled 
with either 1H (=ICPL™-0 reagent) or 2H (=ICPL™-6 reagent) isotope using the ICPL™ methodology according 
to the manufacturer’s instructions29.
Peptides in unlabelled or ICPL™-labelled samples were subsequently separated by reversed-phase 
high-performance liquid chromatography (Dionex, Idstein, Germany) on an XBridge™ C18 column (Waters GmbH, 
Eschborn, Germany) for 1 h resulting in 15 fractions. Fractions were lyophilised and frozen at −20 °C until analysis. 
The fractionated samples were then re-solubilised in 0.1% TFA and mixed with 2.5-dihydroxybenzoic acid and meth-
ylenediphosphonic acid (5 mg/ml each) as the matrix solution. These solutions were then applied to the MALDI-TOF 
target as 2-µl droplets before being allowed to crystallise. In addition, an internal peptide calibration standard was 
applied to each MALDI-TOF target. The mass spectra were acquired using a Bruker Ultraflex I TOF/TOF MALDI 
instrument (Bruker Daltonics, Bremen, Germany) in positive mode with a pulsed nitrogen laser which emitted light 
at 337 nm. The range of analysis was set from m/z 500 to m/z 4000 for the reflector mode. The extraction voltage 
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was 25 kV. Each mass spectrum was obtained as an average of approximately 350–750 single laser shots. With the 
ICPL™-labelled samples, each peptide common to both batches appeared with a defined mass difference Δm of 
6.0204 or a multiple thereof in case of multiple peptide labelling. Peptides in both batches were quantitatively com-
pared by calculating the ratio of the two intensities (intensity of the peak labeled with ICPL™-6-reagent/intensity of 
the peak labeled with ICPL™-0-reagent) obtained for each common peptide labelled with either the 1H or 2H isotope.
In our quantitative analysis using the ICPL™-method, the S/N was set at ≥3. Each batch comparison was 
measured in triplicate. A peak pair was identified only if the mass difference Δm between the two peaks was 
6.0204 or 12.0408 Da to avoid artefacts or interference effects. Furthermore, only peak pairs with a mass deviation 
of ≤ 50 ppm and which were present within the same fraction of a replicate were taken into account.
When two ICPL™ labelled samples are combined according to the manufacturer’s instructions, there may be 
a minimal quantitative difference that might distort the results of concentration comparisons. For this reason, 
we determined a correction factor for each measurement. The correction factor was calculated by determining 
the arithmetic mean of the intensity ratios of all peak pairs found. The intensities of the peaks that were labeled 
with the ICPL™-0-reagents were then multiplied by the correction factor. The intensity ratio of each peak pair 
found was then re-determined using the corrected intensity of the ICPL™-0-labeled peak. Only peak pairs which 
occurred in all three replicates with a mass deviation of ≤50 ppm and in the same or directly adjacent fraction 
numbers were used for our quantitative analysis.
In our comparative analysis of different CHs and their batches, the S/N was set at ≥10 to avoid any arte-
fact measurements. Each CH was measured in triplicate, and peaks representing individual peptides that were 
common to all 3 replicate measurements were used to compare the peptide profiles of 2 or 3 CH preparations 
or batches. The number of detected peaks per 3 replicate measurements of one batch was compared to those of 
another batch in order to determine whether batches differ with respect to the total number of detected peaks. 
Only peaks with a mass deviation of ≤50 ppm and which were present in the same or a directly adjacent fraction 
were considered to be identical.
We further determined various reference values. For this purpose one batch of unlabeled CH-Alpha® (lot 
no. 170/1031) was analyzed by MALDI-TOF MS on two respectively three different days and the respective per-
centage of common peaks was determined. For samples labelled with ICPL™ one batch of Mobiforte® (lot no. 
11/2016/L07) was labelled with either ICPL™-0 or ICPL™-6 isotopes and the number of peaks with an intensity 
ratio ≥0.8 and ≤1.230 were determined.
Specimen Selection for Isolation of FLS. Human synovial tissue containing FLS were obtained from OA 
knee joints (Kellgren-Lawrence classification: 5x grade 4, 1x grade 3) during knee replacement surgery (n = 6, 
age 55–79 years, BMI 23.9–31.6 kg/m2, CRP 1.8 ± 2.3 mg/ml, both genders, 5 male, 1 female). All procedures per-
formed in the study involving human patients were in accordance with the principles outlined in the Declaration 
of Helsinki, and approval by the local Ethical Review Committee of the Faculty of Medicine of the Justus Liebig 
University Giessen had been obtained. All patients provided informed written consent to donate samples for 
research. All patients had comorbidities which included arterial hypertension (5), coronary artery disease (3), 
cardiac arrhythmia (2) diverticulosis (2) and asthma (2). OA patients were selected at random from our ortho-
paedic clinic with the indication for a knee replacement surgery.
Cell Culture of FLS. Human FLS were isolated from synovial membranes as described elsewhere31. FLS were 
cultured in a humidified 10% CO2 atmosphere at 37 °C using DMEM medium supplemented with 1.0 g/l glucose 
and 584 mg/l L-glutamine, 10% foetal bovine serum (FBS), 10 mM HEPES buffer, 10 U/ml penicillin and 0.1 mg/ml 
streptomycin. The experiments were performed with cells harvested at the end of passages 3 to 5. All cells 
tested negative for mycoplasma contamination using the PCR mycoplasma test kit I/C (PromoCell, Heidelberg, 
Germany). The purity of our FLS was ensured by means of fluorescence activated cell sorting (FACS) using mono-
clonal mouse anti-human fibroblast surface protein antibody SM1214PS (clone D7-FIB, Acris Antibodies, Herford, 
Germany) as a positive control. Positive and negative controls were carried out using an anti-HLA-DR-antibody 
and a polyclonal rabbit anti-mouse immunoglobulin conjugated with R-phytoerythrin (code no. R 0439, Dako, 
Glostrup, Denmark). 89% ± 4% of the cultured cells were stained positively for fibroblast-specific antigen.
In our experiment, FLS (approx. 80.000 in each sample) obtained from 6 different patients were cultured for 
48 h in the presence of 0–5 mg/ml CH. CHs were dissolved in 4 mL DMEM with 2% FBS which was also used as 
the vehicle for untreated controls. Cells were serum-starved to 2% FBS for 24 h prior to treatment lasting 48 h. 
Then, the cellular protein content and the levels of different enzymes and cytokines within the nutrient media were 
determined. Cells were lysed using peqGold Trifast™ according to the manufacturer’s instruction, before being 
frozen at −86 °C until further analysis. Nutrient media were frozen at −20 °C in the presence of 10% (vol/vol) 
protease inhibitor cocktail cOmplete™ (Roche Diagnostics, Mannheim, Germany) until further analysis.
Determination of Cellular Protein Content. To normalise the amount of cytokines and enzymes ana-
lysed in culture media, the cellular protein content of FLS was determined in triplicate using the bicichoninic acid 
assay (Pierce™ BCA Protein Assay, Thermo Fischer Scientific, Dreieich, Germany) according to the instructions 
provided by the manufacturer.
Determination of MMP-1, MMP-13, TIMP-3 and NO. MMP-1, MMP-13 and TIMP-3 levels in the 
culture media of FLS were measured using commercially available MMP-1, MMP-13 and TIMP-3 ELISA kits 
from RayBiotech (Norcross, USA) and R&D Systems (Wiesbaden, Germany) respectively, according to the man-
ufacturer’s instructions. Data were normalised with respect to the cellular protein content. NO production of FLS 
was measured in the culture media in duplicate using the Griess reaction after reduction of the nitrate by nitrate 
reductase. Sodium nitrite was used as a standard as previously described in more detail12,32,33.
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Determination of IL-1ß, IL-6, IL-8, PGE2 and TNF-α. IL-1ß, IL-6, IL-8 and PGE2 were measured 
in the FLS culture media using commercially available ELISA kits (IL-1ß Quantikine® ELISA from R&D 
Systems, Wiesbaden, Germany, IL-6 High Sensitivity Kit from eBioscience, San Diego, USA; Human CXCL8/
IL-8 Immunoassay from R&D Systems, Wiesbaden, Germany; PGE2 Kit from Cayman Chemical Company, 
Ann Arbor, USA) according to the manufacturer’s instructions. TNF-α was quantified using two ELISA kits 
with different sensitivities (Human TNF-α kit from R&D Systems, Wiesbaden, Germany and Human TNF-α 
UltraSensitive Kit from Invitrogen™, Karlsruhe, Germany). Cultured medium to be analysed was concentrated 
fivefold using a centrifugal filter (Amicon® Ultra-0.5 ml 3K-device from Merck, Darmstadt, Germany) to allow 
small amounts of TNF-α to be detected. All data were normalised with respect to the cellular protein content.
Statistical Analysis of Data. Each CH preparation was analysed by MALDI-TOF-MS in three independ-
ent measurements (n = 3). Cell culture experiments were repeated 5–6 times using FLS each time obtained from 
different patients (n = 5–6). In order to determine whether different CH preparations or batches differ with regard 
to their peptide profiles, the percentages of common peaks found in two or three CH preparations (Fig. 1, Suppl. 
Table 1) or batches (Figs 2 and 3, Suppl. Table 2) were compared with the respective values from our reference 
measurements using Fisher’s exact test. The number of peptides in two different CH batches or preparations was 
compared using an unpaired, two-tailed t-test. Reproducibility of our MS analysis was determined by comparing 
the percentage of reproducibly detected peaks from each CH preparation and batch using an unpaired, two-tailed 
t-Test (Table 1). The significance threshold was set to p ≤0.05.
In order to check whether two different batches of CHs differed regarding their peptide profiles (Fig. 4, Suppl. 
Table 2), the number of peak pairs with a mean intensity ratio ≥0.8 and ≤1.230 was determined and compared 
with the respective number from our reference measurement using Fisher’s exact test (p ≤0.05). The average 
intensity ratio of a peak pair was determined as the mean of the intensity ratios of the respective three replicates. 
Outliers in the three replicates (1–6 per batch comparison) were not biochemically-physically explainable and 
were excluded by Dean-and-Dixon-outlier-test.
The two-tailed Wilcoxon matched-paired signed rank test was calculated to examine whether different CH 
preparations showed an effect on the levels of cytokines and enzymes within media of cultured FLS. Obtained 
p-values were adjusted for multiple comparison according to Holm. The significance threshold was set at p ≤0.05. 
All data presented within the text are means ± SD. Evaluation of the mass spectrometric analyses was performed 
using flexAnalysis 3.4 (Bruker Daltonik, Bremen Germany). Statistical analysis and graphics were created using 
Prism® 5.03 (GraphPad Software Inc., La Jolla, CA, USA).
Results
MALDI-TOF-MS Analysis of CHs. MALDI-TOF-MS, performed in reflector mode, covering mass-to-charge 
ratios (m/z) of between 500 and 4000, showed remarkable differences between the peptide profiles of differing CH 
preparations and between those of some CH-batches. As shown in Fig. 1, the batches of Mobiforte®, CH-Alpha® 
and Peptan® B 2000 differed between each other with respect to the total number of reproducible peaks represent-
ing collagenous peptides. We determined significantly less peptides in two batches of CH-Alpha® (103, 113 peaks) 
than was the case in two batches of Mobiforte® (146, 166 peaks) and of Peptan® B 2000 (154, 196 peaks).
Figure 1. Number of peptides in different batches of Mobiforte®, CH-Alpha® and Peptan® B 2000 as 
determined by MALDI-TOF-MS analysis. The numbers outside the diagram represent the number of total 
common peaks obtained from 3 replicate measurements, with each peak representing a peptide of the 
corresponding batch. The numbers in the intersections of the Venn diagrams are peptides shared by one, two or 
by all preparations. Analysed batches: (A) CH-Alpha® (lot no. L115/1031), Peptan® B 2000 (lot no. 1048665) 
and Mobiforte® (lot no. 11/2016/L07); (B) CH-Alpha® (lot no. L88/1031), Peptan® B 2000 (lot no. 1266793/x) 
and Mobiforte® (lot no. 11/2016/L06).
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The batches of the three different CH preparations also differed with regard to their peptide composition. 
Figure 1 demonstrates that only a few common peptides were found in any two or even all CH preparations. 
Illustrating this fact, the three CH preparations shown in Fig. 1 had only 6 or 9 peptides in common, depending 
Figure 2. Comparative analysis of MALDI-TOF mass spectra obtained from two batches of (A) Mobiforte®, 
(B) CH-Alpha®, and (C) Peptan® B 2000. Each peak of the rug plots represents a common peptide obtained 
from 3 replicate measurements in one batch. If a common peptide of one batch was also found in the other 
batch, it is marked as a continuous peak.
Figure 3. Comparative analysis of MALDI-TOF mass spectra obtained from three different CH-Alpha® 
batches. The mass spectra of the batches with lot no. L115/1031, L88/1031 and L170/1031 are presented as (A) 
a rug plot, and (B) a Venn diagram. Each peak of the rug plot represents a common peptide obtained from 3 
replicate measurements of one batch. If a common peptide of one batch was found in two or three batches, it is 
marked as a continuous peak. The numbers outside the Venn diagram are the number of total peptides present 
in each batch. The numbers in the intersections are peptides shared by one, two or by all batches.
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on which batches were being compared. CH-alpha® and Mobiforte® shared 11 or 17 peptides and the two bovine 
CH preparations CH-Alpha® and Peptan® B 2000 had 16 or 21 peptides in common, depending on which 
batches were being compared. The percentage of peaks common to all three CH preparations shown in Fig. 1 was 
2%, which was significantly less than our reference value of 42% (p < 0.0001). The reference value was obtained by 
CH-preparation Lot No.
Total number of peaks
per replicate
(mean ± SD)
Percentage of reproducible peaks
per replicate
(mean ± SD)
Peptan® B 2000
1048665 365/266/243(291 ± 65)
46.3/58.3/63.8 
(56 ± 9)
1266793/x 324/277/319(307 ± 26)
60.5/70.8/61.4 
(64 ± 6)
Mobiforte®
11/2016/L07 245/288/320(284 ± 38)
59.6/50.7/45.5
(52 ± 7)
11/2016/L06 282/221/268(257 ± 32)
58.9/ 75.1/61.9
(65 ± 9)
CH-Alpha®
L115/1031 170/174/165(170 ± 5)
60.6/59.2/62.4 
(61 ± 2)
L88/1031 164/212/182(206 ± 40)
68.9/ 53.3/62.1
(61 ± 8)
L170/1031 172/171/151(165 ± 12)
55.8/56.1/63.6 
(59 ± 4)
Table 1. Total number of peaks detected as well as percentage of reproducible peaks in each of the three 
replicated measurements of different CH preparations using a S/N of ≥ 10.
Figure 4. The relative abundance of peptides in different batches of (A) Mobiforte® (lot no. 11/2016/L06 and 
11/2016/L07), (B) CH-Alpha® (lot no. L115/1031 and L88/1031), (C) Peptan® B 2000 (lot no. 1048665 and 
1266793/x), and (D) reference measurement using Mobiforte® (lot no. 11/2016/L07) labelled with both 
ICPL™-0 and ICPL™-6 isotopes. To compare the concentrations of peptides, the ratios of peak intensities for 
each peak pair were determined using the ICPL™-labelling method in the replicates. The mean ratios of peak 
intensities found in each batch are presented (n = 2–3). Peak pairs with an intensity ratio ≥0.8 and ≤1.2 were 
considered to represent equal intensities of labelled peak pairs and as such equal concentrations of the same 
peptide in both batches30.  = mean ratio of peak pair >2.
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determining the percentage of common peaks in one CH preparation (CH-Alpha® lot no. L170/1031) over three 
consecutive days (Suppl. Fig. 1). Thus a value for the reproducibility of repeated MALDI-TOF measurements was 
obtained.
Furthermore, we also compared two or three batches of Mobiforte®, CH-Alpha® and Peptan® B 2000 and 
observed that some CHs have batches showing markedly different peptide compositions (Figs 2 and 3). The two 
Mobiforte® batches revealed 109 peaks (54%) in both preparations, whereas the two CH-Alpha® batches only 
revealed 63 common peaks (41%). However, only 45 common peaks (25%) were detected where three different 
CH-Alpha® batches (Fig. 3) were compared with one another. Figure 2C illustrates that the two Peptan® B 2000 
batches revealed 83 peaks (31%) in common. Our reference measurements (Suppl. Fig. 1) showed that only 
69 (51%) and 60 (42%) of the peaks were common to two or three independent measurements of the same 
CH-Alpha® batch (lot no. L170/1031). As such, the two batches of Peptan B 2000 (p = 0.006) and the three dif-
ferent batches of CH-Alpha® (p = 0.016) differed with respect to the percentage of peaks common to all batches. 
Compared with the reference measurements (51%), the percentages of common peaks between two batches of 
CH-Alpha® (41%) and Mobiforte® (54%) were similar. A list of the analysed peaks determined in the different 
CH batches is shown in Suppl. Tables 1 and 2. In none of the batch comparisons did the number of detected peaks 
differ significantly from one another (CH-Alpha® p = 0.32, Mobiforte® p = 0.40 and Peptan® B 2000 p = 0.44) 
(Table 1).
We determined whether MALDI-TOF-MS delivers reproducible numbers of peaks at a signal-to-noise ratio 
(S/N) of ≥10. The reproducibility was quantified by counting the number of peaks in triplicate for each CH 
preparation or batch and calculating the percentage of reproducible peaks found. The mean percentage of repro-
ducible peaks was 60%, and revealed no significant differences in any of the investigated CH preparations or 
batches (Table 1).
Quantitative MALDI-TOF-MS Analysis of CHs with the ICPL™ Labelling Method. The iso-
tope coded protein label (ICPL™) technique was applied to compare the concentrations of peptides in different 
batches of Mobiforte® (lot no. 11/2016/L07 and 11/2016/L06), CH-Alpha® (lot no. L115/1031 and L88/1031), 
and Peptan® B 2000 (lot no.1048665 and 1266793/x) by MALDI-TOF-MS (Fig. 4). The ratios of peak intensities 
of each pair of differently isotope-labelled peaks were determined, and ratios lying in the range of 1.0 ± 0.2 were 
considered to represent equal intensities of labelled peak pairs and as such equal concentrations of the same pep-
tide in both batches30. Figure 4 shows that in some cases there are markedly different concentrations of peptides 
analysed in different batches of the same CH preparation.
The percentage of peak pairs considered as equivalent from the two batches of Mobiforte® was 78% (Fig. 4A, 
Suppl. Table 1), whereas these figures for CH-Alpha® and Peptan® B 2000 were only 47% and 34%, respectively 
(Fig. 4B,C; Suppl. Table 1). Our reference measurement as shown in Fig. 4D revealed that 78% of all determined 
ratios of peak intensities lay within the limits of between 0.8 and 1.2. As such the batch comparisons for the 
CH-Alpha® and Peptan® B 2000 batches revealed that these preparations were significantly more inconsistent 
compared to the comparison of the reference measurements (with p values of 0.012 and ≤0.001, respectively). 
Remarkably, compared with our reference value of 78%, no statistically significant inconsistency was observed 
between the two Mobiforte® batches analysed.
The Collagen Hydrolysates and the Levels of MMPs, cytokines, PGE2 and NO. Since we previ-
ously reported that CH preparations differ with respect to their potential to modulate the metabolism of human 
articular cartilage explants11,12, we then investigated batch specific biological effects on cultured human FLS. Our 
analysis revealed that none of the CH preparations or batches showed any statistically significant activity regard-
ing the levels of MMP-13, TIMP-3 IL-1ß, IL6, TNF-α, PGE2 or NO, even though a broad range of concentrations 
between 0.1 and 5 mg/ml was tested (data not shown).
IL-8 and MMP-1 after Treatment with Different Batches of CHs. Figure 5 demonstrates that only 
Peptan® B 2000 considerably stimulated the release of IL-8 and MMP-1 into the culture media of synoviocytes 
although no statistical significant effect could be found. Figure 5 also reveals that only one batch of Peptan® B 
2000 (lot no. 1048665) was able to display these effects on cultured human FLS.
Discussion
The application of nutraceuticals including CHs is becoming increasingly popular even though there is only lim-
ited information regarding their clinical efficacy, mode of action or safety22. We previously reported that several 
CH preparations obtained from different sources can vary markedly with respect to both their effects on human 
articular cartilage as well as their biochemical composition11,12. Based on these results, the aim of our current 
study was to deepen our insights into the natural product CH by comparing both the peptide composition as well 
as the bioactivity of individually produced batches of various CH preparations. Our novel findings are that (a) the 
peptide composition and relative abundance of specific peptides can differ between two batches of the same CH 
preparation, and that (b) the altered peptide composition of the two production batches did not lead to inconsist-
ent bioactivity towards cultured FLS using a limited number of pharmacological targets.
Using MALDI-TOF-MS, we found that the peptide composition differed significantly between the three 
bovine or porcine CH preparations, namely Peptan® B 2000, CH-Alpha® and Mobiforte®. The two batches 
obtained from the bovine Peptan® B 2000 and those from the porcine Mobiforte® differed significantly from 
the two bovine CH-Alpha® batches regarding the total number of peaks representing peptides as well as their 
individual peptide compositions. Only 2% of all peptides were shared by all three CH preparations, whereas the 
two bovine preparations shared 15% or 18% peptides, depending on the batches analysed. Our data indicate that 
both the source as well as the production method may have a lasting effect on the peptide composition of CHs.
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Furthermore, we report here for the first time that even two batches of the same CH preparation can some-
times display markedly altered peptide profiles. We determined that only 31% of the peaks were common to two 
batches of Peptan® B 2000, which was significantly less than was the case with our reference measurement (51%). 
Similar levels of peak consistency were found between both batches of Mobiforte® (54%) and CH-Alpha® (41%). 
However, when we compared three different batches of CH-Alpha®, significantly fewer numbers of common 
peaks (25%) were found compared to the corresponding reference measurements (42%). Remarkably, the total 
number of peptides did not differ between the three batches of CH-Alpha®. Thus, as a natural product, some 
inherent alteration in peptide composition may occur, but it should nevertheless be possible to avoid excessive 
batch inhomogeneity so that more reproducible compositions of CH batches can be achieved.
By applying the ICPL™-methodology, we also investigated whether two batches of Mobiforte®, CH-Alpha® 
or Peptan® B 2000 differ with respect to the relative abundance of their common peptides. We found that only 
the two tested batches of Mobiforte® were produced in a quantitatively reproducible manner showing equivalent 
amounts of the most common peptides. This was not observed in the batch comparisons for CH-Alpha® or 
Peptan® B 2000, where major inconsistencies were revealed.
Taken together, our comparative chemical analysis of the peptide profiles of two batches revealed that reason-
able reproducibility could only be seen for the Mobiforte® batches. The CH-Alpha® batches differed mainly due 
to altered concentrations of peptides, whereas the two Peptan® B 2000 batches showed discrepancies regarding 
both the actual composition and abundance of the peptides.
For unlabelled samples, a S/N of ≥10 was chosen in order to avoid any artefact effects. A S/N of ≥3 was cho-
sen for the ICPL™-labelled samples in order to increase the sensitivity since this labelling method provides an 
additional possibility for peptide identification by determining peak pairs. A correction factor was determined 
for each measurement to correct for minimal quantitative differences between two combined ICPL™-labelled 
samples. Each CH was measured in independent replicates (n = 3), and only common peaks between all three 
replicate measurements were considered as peptides. All measurements were performed in the precise reflector 
mode by MALDI-TOF-MS. The mass range in our analysis was set from m/z 500 to 4000. Thus, peptides with 
higher mass numbers were not detected by our measurements. However due to their mean molecular mass of 2 to 
6 kDa10,13, the measured mass range was sufficient to allow general statements about CH preparations to be made.
Reproducibility of measurement is still a major challenge in MALDI-TOF-MS. We therefore tested the repro-
ducibility of our MS-method by investigating whether the percentage of reproducible peaks, as determined in 
triplicate for each preparation/batch, remained the same at a S/N of ≥10. The mean percentage of reproducible 
peaks was 60% and did not significantly change in any of the investigated CHs, so that different CH preparations 
and batches could be considered as comparable. We also determined various reference values. For this purpose, 
one batch of unlabelled CH-Alpha® (lot no. L170/1031) was analysed by MALDI-TOF MS on two and three 
different days. Only 51% or 42% of the peaks were found to be common after two or three days, respectively. For 
samples labelled with ICPL™, one batch of Mobiforte® (lot no. 11/2016/L07) was labelled once with ICPL™-0 and 
once with ICPL™-6 isotopes. In this reference measurement, only 78% of all determined peptide concentrations 
were found to be equivalent. Our reference values are markedly below the theoretically achievable 100%, and thus 
reflect the limited reproducibility of the MALDI-TOF-MS analyses.
When comparing the number of common peaks found in both batches of CH preparations using the 
ICPL™-isotope labelling method, fewer peptides were found than was the case with the unlabelled samples. We 
only counted those labelled peptide pairs which had a mass difference of 6.0204 or 12.0409 to avoid any effects of 
interference and possible false-positive results, although peptide pairs with greater mass differences were theo-
retically possible. We also assume that it was only those peptides that were present at higher amounts within the 
CH-batches that might have been labelled adequately with the ICPL™ reagents to allow a subsequent detection.
Since different CHs can stimulate a catabolic reaction in human cartilage explants11,12, we investigated whether 
the different CHs had an effect on cultured FLS obtained from human OA knee joints. Our study indicates that 
Figure 5. The effects of two different Peptan® B 2000 batches on (A) IL-8 and (B) MMP-1 content in culture 
media expressed as pg per µg cellular protein content. IL-8 and MMP-1 were quantified by ELISA in the 
media of cultured fibroblast-like synoviocytes treated with 0–5 mg/ml Peptan® B 2000. Data are expressed as 
means ± SD (n = 4–6). □ = Peptan® B 2000, lot no. 1048665; ■ = Peptan® B 2000, lot no. 1266793/x.
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two batches of the same CH preparation have indeed no significant different effect on FLS using a limited number 
of pathophysiological relevant targets.
A daily dose of 10 g CH is recommended by some manufacturers, so that the serum levels of CH are most 
likely below 2 mg/ml and probably even below 1 mg/ml due to the (assumed) restricted bioavailability11,12. Thus 
in our experiments, we included physiologically achievable concentrations which were also similar to those used 
in most other in vitro studies carried out using chondrocytes11,12,14,25,34. However, in our study, a markedly elevated 
release of proinflammatory mediators and enzymes could often only be detected at CH concentrations equal or 
above 1–2 mg/ml, i.e. levels which are probably not achievable in synovial fluid in vivo. Furthermore, CHs admin-
istered in vivo are subjected to further metabolism during resorption and circulation so that only a small amount 
of orally given peptides will ultimately reach the joints without being modified12.
Only one batch of Peptan® B 2000 showed an increased release of MMP-1 into culture media which was 
non-significant probably due to the small number of replicates. An increased release of various MMPs, such as 
MMP-1, is a characteristic feature of synovial inflammation during OA which contributes to tissue damage and an 
inflammatory response5,35–37. We previously reported about the effects of Mobiforte®, CH-Alpha® and Peptan® 
B 2000 on cartilage explants11,12 using other batches. Similar to our current study, a number of CHs displayed a 
few proinflammatory effects on cartilage explants. As one example, when cartilage explants were incubated with 
Mobiforte®, increased levels of NO, IL-6 and MMPs were found in the culture medium12, whereas in this study 
neither batch of Mobiforte® displayed an effect on FLS. We assume that these differences may be due to batch 
specific and/or cell type specific effects. Also, our previous studies11,12 revealed that none of the preparations even 
when used at high concentrations of 10 mg/ml were cytotoxic to chondrocytes of the superficial, intermediate and 
radial zones of explanted cartilage.
Conclusion
This study clearly shows that two batches of the same CH preparation may differ significantly with regard to their 
biochemical composition. However, further studies are needed to verify whether different CH batches possess 
equal pharmacological efficacy by analyzing a much broader range of physiological relevant targets. We conclude 
that both the source and the production process ultimately determine the composition and reproducibility of the 
various CH batches. Based on our findings, it is doubtful whether general statements on the effectiveness, safety, 
and mode of action of CH preparations and even different batches of CH preparations can be made. As such, 
our results only serve to reinforce the assumption that the biological effects of CHs observed by us and others 
are brought about only by a small number of the individual bioactive peptides11,12,28. Although the results of our 
study can only be transferred with considerable reservations to the much more complex situation seen in vivo, 
they suggest a thorough and broad examination of each and every CH preparation with regard to their ability 
to reproducibly induce various effects both in vitro and in vivo so that they can be attested as safe and effective 
nutraceuticals for OA patients.
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